Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.




Follow This Show

Stay in the know about new episodes and updates.
CureTalks features leading medical experts in conversation with a panel of patients/advocates about latest research and treatments under development.

Upcoming Broadcasts

This is the first of a 3 part series of talk on high risk smoldering myeloma and its treatments. Of all the other myeloma types high risk myeloma is the most difficult to treat. This underscores the need to come up with improved therapies for patients belonging to this group. With the goal of curing 30-50% of high risk smoldering patients, the upcoming ASCENT trial plans to use aggressive treatments with the addition of daratumumab (anti-CD38) into the combination. We are talking to Dr.Shaji Kumar of Mayo Clinic Rochester about the nuances of the ASCENT clinical trial. Dr. Shaji K Kumar is Professor of Medicine at the Mayo Clinic College of Medicine and a consultant, Mayo Clinic Division of Hematology. Dr. Kumar is board certified in medical oncology and hematology. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association of Clinical Research, American Society of Blood and Marrow Transplantation, American Medical Association, Association of Physicians of India, and the European Hematology Association. His laboratory focuses on development of novel drugs for treatment of myeloma and he has been published in numerous peer-reviewed journals including British Journal of Haematology, Blood, American Journal of Hematology, and Bone Marrow Transplant on this topic. RSVP HERE!
Reminder Edit Reminder

On-Demand Episodes

A modern couple has various options to build their family at their choice of time with the advent of ground breaking reproductive technologies made available by our scientific fraternity. For either medical or non medical reasons, more... more

Recent introduction of new therapies has significantly improved outcomes for patients diagnosed with multiple myeloma. However, cures remain rare in myeloma and most people may eventually relapse. If we can better understand... more

At all stages of and levels of prostate cancer, whether you have low, intermediate, or high risk disease, whether you are newly diagnosed, have recurrent disease or your prostate cancer has advanced and metastasized, the... more

Cancer drugs cost more than $100,000 per year and continue to increase. Medicare has proposed major changes to Medicare Part B in an attempt to slow the explosion in healthcare expenditures. In addition, a recent ?report? by... more

We are talking to Dr. Richard Paulson on fertility in older women. Dr. Richard J. Paulson is the holder of the Alia Tutor Chair in Reproductive Medicine, and is Professor and vice-chair, Department of Obstetrics and Gynecology, and Chief of... more

Clinical trials of new combination therapies are showing promising results and can be game changers in myeloma treatment - combining standard drugs with monoclonal antibodies, myeloma vaccine combinations, t-cell therapies with... more

Almost half of all pregnancies end in a miscarriage, most of them occurring within few weeks of conception. While there are a number of known risk factors such as maternal age, history of miscarriage, and infertility, there are others like alcohol... more

FDA recently approved daratumumab (Darzalex) to treat patients with multiple myeloma who have received atleast three prior treatments. Daratumumab is the first monoclonal antibody approved for treating myeloma and provides another... more

Recent advances in prostate cancer has led to the discovery of many new imaging and genomic tests. Information on the new tests and techniques can help patients in making informed decisions regarding their prostate cancer diagnosis,... more

2015 saw a lot of action in the Myeloma world. Four new drugs were approved by the FDA increasing treatment options and allowing new combination regimens; promising immunotherapy research results will see these being used in clinical... more
Show Extras